Pulmonary Embolism (PE): Warning Signs, Emergency Care & Treatment

Pulmonary embolism describes embolic material lodging in pulmonary arteries—almost always thrombus originating from lower-limb or pelvic deep veins, less often from upper-extremity lines or right-sided cardiac sources. Obstruction raises pulmonary vascular resistance, promotes ventilation–perfusion mismatch, and loads the right ventricle; severe acute pulmonary hypertension can precipitate circulatory collapse. PE forms one limb of venous thromboembolism alongside deep vein thrombosis, sharing risk factors aligned with Virchow’s triad (stasis, endothelial injury, hypercoagulability).

Nurses translate pathophysiology into observable cues: unexplained hypoxia, disproportionate tachycardia, pleuritic pain with clear lungs, and bedside hypotension should trigger escalation, monitoring, and protocolised handoffs rather than “benign tachycardia” labels—especially when sepsis, pneumonia, and heart failure therapies overlap.

International guidance stratifies acute PE by haemodynamics, biomarkers, and imaging markers of right ventricular dysfunction to route patients toward ward monitors, higher-dependency beds, or reperfusion teams. PESI or sPESI calculators summarise comorbidity and illness severity for early discharge consideration in low-risk cohorts when local pathways support outpatient direct oral anticoagulant protocols (prescriber decision). Intermediate-risk (“submassive”) patients may look “stable” yet harbour RV dysfunction—where protocols apply serial biomarkers, ultrasound, or monitored telemetry on designated units.

↔On a small screen, swipe or scroll sideways to see the full table.

Presentations vary from nearly silent small peripheral emboli to sudden cardiovascular collapse. Dyspnoea—often abrupt—is the most common complaint. Pleuritic chest pain reflects peripheral infarction or pleural irritation; central clot burden may produce angina-like discomfort that challenges nurses to keep acute coronary syndrome in the simultaneous differential. Haemoptysis is less frequent but raises concern for pulmonary infarction or alternative pathology.

Atypical or subtle patterns

• Isolated syncope or presyncope—especially in young ambulatory patients—still requires PE work-up when Wells criteria or gestalt suspicion stays elevated.
• The anxious “hyperventilating” label misclassifies many PE patients; pair psychological reassurance with objective vital and gas exchange trends.
• Patients with chronic cardiopulmonary disease may show only marginal SpO₂ change—lean on trend, exertional desaturation, lactate, and clinical scores.

Most emboli arise from lower-extremity thrombi provoked by surgery, trauma, cancer, prolonged immobility, oestrogen therapy, pregnancy, thrombophilia, or prior VTE. Air, fat, or tumour embolism is rare but documented—context matters (orthopaedic procedures, childbirth trauma, marrow infarction). Critically ill patients accrue multiple simultaneous risks: paralysis, central lines, infection-related inflammation.

Nursing history targets timing of symptom onset, hormonal medications, recent travel, prior clots, active malignancy therapies, and mechanical prophylaxis gaps; document baseline functional capacity to sense later deterioration accurately.

Validated Wells scores (and pregnancy-adapted variants) establish pretest probability. Age-adjusted D-dimer thresholds rule out PE only when scores land in low-probability strata and the assay is negative—never misapply in high pretest scenarios. CT pulmonary angiography remains dominant for direct clot visualisation when renal function, contrast allergy mitigation strategies, and institutional access permit. Echocardiography supports RV dysfunction assessment and can aid instability work-ups; ventilation–perfusion scanning or cross-sectional alternatives appear when radiation or iodinated contrast avoidance is paramount.

Laboratory partners include troponin and BNP or NT-proBNP trends when RV strain suspected; arterial blood gas or venous lactate augments perfusion assessment. Bedside ultrasound programmes may integrate into shock protocols under credentialled operators.

↔On a small screen, swipe or scroll sideways to see the full table.

1. Stabilise & score: Control airway and oxygen, establish monitoring per NEWS2 or equivalent, calculate Wells PE score, document syncope, BP trends, and bleeding risks before anticoagulation.
2. Rule-in tests: If intermediate/high probability or D-dimer positive, arrange definitive imaging in parallel with baseline labs—coordinate safe transport with an escort for unstable patients.
3. Anticoagulate: When diagnosis confirmed and no absolute contraindication, initiate pathway-specific therapeutic anticoagulation promptly—often parenteral heparin bridging to apixaban or warfarin per local formulary.
4. Rescue tier: For shock or sustained hypotension, escalate to senior clinician + critical care + reperfusion-centre discussion (thrombolysis, interventional retrieval, surgical embolectomy).
5. Safety net: Educate on bleeding red flags, medication adherence, compression or mobility advice, and timely thrombosis follow-up.

Anticoagulation remains standard for acute PE without contraindication; direct oral anticoagulants are first-line in many non-cancer, hemodynamically stable patients per CHEST and ESC-aligned pathways. Cancer-associated thrombosis usually continues with weight-adjusted low-molecular-weight heparin or approved oncology dosing schedules rather than ad hoc switching. Warfarin persists when interacting medications, mechanical valves, or nuanced antiphospholipid syndromes dictate INR surveillance.

Massive PE with shock may receive systemic fibrinolysis when bleeding risk is acceptable; catheter-directed therapy or surgical embolectomy stays interventional-team territory. Inferior vena cava filters occupy a narrow niche when anticoagulation is truly impossible transiently—never a substitute for medication when bleeding is manageable.

• Recheck observations after each anticoagulant bolus or infusion rate adjustment—map vitals to institutional escalation charts.
• Renal dosing: verify creatinine clearance pathways for LMWH versus DOAC choices; involve pharmacy early.
• Platelet monitoring for heparin-induced thrombocytopenia suspicion when UFH exposure extends beyond brief bridges—know local platelet surveillance cadence.
• Transitioning from parenteral to oral agents requires aligned stop/start times; nurses should reconcile MAR entries during handoffs.
• Document neuro checks after thrombolysis per critical care protocol; maintain strict blood pressure corridors ordered by specialists.

• Recurrent PE or extension despite therapy—suggest adherence gaps, cancer-related hypercoagulability, or inadequate anticoagulation intensity.
• Right ventricular failure progression, cardiogenic shock, or multisystem hypoperfusion.
• Major bleeding (intracranial, gastrointestinal) from anticoagulation or rescue lysis—activate reversal pathways per protocol.
• Chronic thromboembolic pulmonary hypertension—long-term follow-up clinics screen persisting exertional symptoms.

Apply VTE prophylaxis bundles for at-risk inpatients—early mobilisation, pharmacologic prophylaxis when bleeding risk permits, and mechanical adjuncts such as sequential compression devices when anticoagulants are withheld peri-procedurally. Educate ambulatory patients on hydration, leg exercises on long journeys, and prompt review if calf symptoms emerge after hospital discharge.

Early diagnosis with effective anticoagulation reduces short-term mortality dramatically; intermediate and high-risk cohorts inherit longer monitoring intervals. Recurrent VTE risk climbs with malignancy, unprovoked events, or persistent provoking factors—anticoagulation duration is individualized after shared decision-making, not guessed at the nursing station.

Patients often interpret dyspnoea as anxiety; your documentation of objective SpO₂, respiratory rate, heart rate, and escalation conversations protects them later. When teams anchor on normal D-dimer in an older septic patient, politely surface guideline limits—nurses are safety redundancies. Families may push for ambulation before bleeding risk is assessed; align mobility plans with the treating team’s anticoagulation timing.

• SpO₂, respiratory rate, work of breathing; oxygen delivery device and humidification needs.
• Heart rate, blood pressure, perfusion, urine output where shock is a concern.
• Pain scores and positioning tolerance ahead of imaging.
• Gum bleeding, IV site oozing, stool colour, menorrhagia—structured bleeding survey each shift on anticoagulation.
• Mental status—PE with hypoxia may present as agitation or fatigue before obvious cyanosis.

Worsening tachycardia without fever, widening A–a gradient, climbing oxygen requirement, or rising lactate in a patient with known/suspected PE should trigger immediate bedside review—consider repeat imaging, thrombolysis eligibility, and critical care transfer. Invoke rapid response activation per facility policy when scores cross thresholds; do not silo concerns awaiting the next ward round if instability is evolving.

• Maintain telemetry when dysrhythmia or RV strain risk is flagged.
• Optimise VTE prophylaxis education for immobile patients; reinforce oxygen titration targets and humidification comfort.
• Line stewardship: preserve patency for potential contrast CT, analgesia, or thrombolysis infusions—use ANTT for every access episode.
• Psychological support: sudden PE diagnoses frighten patients; pair honest prognosis ranges with concrete follow-up appointments.

These NCLEX-style clinical judgment practice items focus on the nursing priorities for this condition — recognise cues, escalate red flags, take safe action and evaluate outcomes (NCSBN Clinical Judgment Measurement Model) — through Priority FIRST, SATA, deterioration trends, multi-patient triage, ordered response, matrix matching and cloze drops on the topic of Wells pathways, anticoagulation safety, massive PE rescue, and telemetry stewardship—reflecting Clinical Judgment Measurement Model priorities for recognition, response, and risk mitigation.